European Community Advisory Board – ECAB
The European Community Advisory Board – ECAB
The European Community Advisory Board – ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient community to provide meaningful, independent, and valued input in HIV treatment and prevention research.
EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV (and related co-infections) drug-development, promotes community input in the life cycle of new medicines, vaccines, cure programmes and diagnostics R&D, as well as access to treatment in the European region as defined by the World Health Organisation.
ECAB is a high-level scientific platform, representing the perspective of the HIV community, that brings together civil society, scientific researchers, the pharmaceutical industry and occasionally international institutions to address key science issues related to HIV and its main co-infections like viral hepatitis, tuberculosis.
ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena. It is a volunteer, community-based structure, also collaborating actively with national and regional Community groups in Europe and other groups sharing the same philosophy in other geographical areas. The majority of ECAB members are living with HIV. ECAB members represent the diverse needs, interests, and concerns of the entire spectrum of the European HIV patient community (women, men who have sex with men, injecting drug users, ethnic minorities, people in detention, and other vulnerable groups).
ECAB aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to provide community input, under confidentiality, in the advances in HIV drug development and related co-infections, and the development of European research on HIV co-infection.
ECAB ‘s work includes:
- Promoting community input in the HIV (and related) medical R&D programmes
- Reviewing clinical trial protocols giving the point of view and the needs of People Living with HIV (PLHIV)
- Representing the HIV Community in European projects on HIV research and patient participation in life cycle of new medicines
- Promoting universal access to fair, sustainable, affordable drugs
Members of the ECAB meet in Brussels on a regular basis (see calendar of meetings).
Giorgio BARBARESCHI (EATG Office, Belgium)
Luís MENDAO (Portugal)
Steering Committee Members:
Ivana BENKOVIĆ (Croatia)
Giulio Maria CORBELLI (Italy)
Sean HOSEIN (Canada)
Maryan SAID (Norway)
Bernard VUKAS (Croatia)
Nikos DEDES (Liaison ECAB/Board of Directors, Greece)
Esther DIXON-WILLIAMS (Liaison ECAB/Board of Directors, United Kingdom)